CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer

Stopped low accrual made the study no longer feasible/decision not related to safety and efficacy

Conditions

• Pain
• Neoplasms
• Chronic Pain

Interventions

• DRUG: Cebranopadol
• DRUG: Morphine Prolonged Release

Sponsor

Tris Pharma, Inc.